A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency (CONFIRM-HF)
A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Sponsor: ICON Clinical Research
This PHASE4 trial investigates Chronic Heart Failure and Iron Deficiency and is currently completed. ICON Clinical Research leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — May 2020 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ICON Clinical Research
- Vifor Pharma
For direct contact, visit the study record on ClinicalTrials.gov .